Revenue from operations increased 7.37% year on year (YoY) to Rs 363.73 crore in Q1 FY27.
Profit before tax (PBT) rose 45.38% to Rs 129.12 crore in the June quarter from Rs 88.81 crore in the year-ago period.
Milind Thatte, managing director of P&G Health India, said the company began FY27 on a strong note, carrying forward the growth momentum from the previous fiscal. He attributed the performance to sustained top-line and bottom-line growth, driven by strong consumer response to the company's science-backed innovations, new consumer communication initiatives, and strengthened go-to-market and supply chain capabilities. He added that the company remains focused on delivering balanced growth and long-term value creation through its portfolio of trusted brands, product superiority, constructive disruption, productivity and an agile operating model.
Procter & Gamble Health is one of India's leading vitamins, minerals and supplements (VMS) companies. Its portfolio includes Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion.
The scrip declined 5.72% to Rs 6,089 on the BSE.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
"Contents which are exclusively for Non-Broking Products/Services, "Mutual Fund, Mutual Fund-SIP, Research reports, Insurance, etc. where the Member is just a distributor. These are not Exchange traded product and the Member is just acting as distributor. It should also state that all disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism."